Main Navigation
Mercia
Ventures
Debt
Private equity
Contact us
About us
Investment strategies
Investor area
PLC
EIS
VCT
Contact us
Audience
|
Change
Ventures
Debt
Private equity
Contact us
About us
About us
Our history
Our vision and values
University partnerships
Team
Careers
Portfolio
Sustainability
Strategies
Our investment strategy
Our funds
Strategic assets
Property development finance
EIS & VCT
For shareholders
Share price
Board of directors
Financial reports & presentations
Regulatory news
Corporate governance
AIM Rule 26
Organisational structure
Annual Report
VCT
Northern Venture Trust
Northern 2 VCT
Northern 3 VCT
Insights & Research
Hub
Ventures
Debt
Private equity
Contact us
About us
Investment strategies
Investor area
PLC
EIS
VCT
Contact us
About us
About us
Our history
Our vision and values
University partnerships
Team
Careers
Portfolio
Sustainability
Strategies
Our investment strategy
Our funds
Strategic assets
Property development finance
EIS & VCT
For shareholders
Share price
Board of directors
Financial reports & presentations
Regulatory news
Corporate governance
AIM Rule 26
Organisational structure
Annual Report
VCT
Northern Venture Trust
Northern 2 VCT
Northern 3 VCT
Insights & Research
Hub
test documents
PsiOxus Therapeutics announces positive study results of oncolytic vaccine enadenotucirev at 2014 ASCO Annual Meeting
View
PolyTherics and Antitope form Abzena
View
BioExtractions Wales completes funding round for innovative extraction service
View
Mercia Fund Management launches flexible, cost effective workspace for early stage gaming and technology businesses
View
Mercia Fund Management agrees second stage funding for VirtTrade
View
Mercia Fund Management backs social media duo Crowd Reactive and TorqBak
View
Thalia Design Automation Ltd completes A round funding and prepares to launch suite of Analog and Power design optimisation tools
View
Mercia Fund Management boosts portfolio with Canary investment
View
Mercia mention in FT.com “Getting exposure to UK tech”
View
PolyTherics and MacroGenics extend Collaboration to Produce Novel Antibody Drug Conjugates
View
Previous
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
Next
Loading...
Loading...
Disclaimer
Which of these options best describes you?
Please wait...
Disclaimers
Which of these options best describes you?
Please wait...
Loading...
Loading...
Disclaimer
Which of these options best describes you?
Please wait...
Disclaimers
Which of these options best describes you?
Please wait...